Project Grant K99DA061974

Award Date 6/15/25
Completion Date 5/31/27
Dollars Obligated $207K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on investigating the role of the glucocorticoid receptor (GR) as a neuromolecular mechanism regulating inhibitory control processes, such as reward sensitivity and rash impulsivity, which contribute to maladaptive behaviors associated with substance use disorders. The $127,635 award, which runs from June 2025 to December 2025, will employ...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to map molecular changes in the habenula brain region associated with chronic opioid exposure. The $284,040 grant will be used to conduct integrated single-cell and spatial transcriptomic analyses in rodents to identify projection-specific molecular pathways impacted by opioid use disorder. The research aims to generate a comprehensive...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $373,300.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the role of the nucleus accumbens in cue-reward learning. The study aims to investigate how precisely timed inhibition of specific neuronal populations in the nucleus accumbens contributes to the selective learning and response to...
The National Institute on Drug Abuse (NIDA) awarded a $1,039,420 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to the Medical University of South Carolina (MUSC) to conduct research on the neural circuits underlying the facilitation and disinhibition of opioid and alcohol seeking behaviors. The project will use innovative tools like single-nucleus RNA sequencing, spatial sequencing, in vivo calcium imaging, and holographic optogenetics to characterize the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is supporting research to investigate the role of valence encoding amygdala ensembles in avoidance behavior. The $148,403 award, effective from December 1, 2024 to November 30, 2026, aims to: 1) determine how functional antagonism of valence-selective neural ensembles is generated in the basolateral amygdala, 2) identify how these antagonistic valence...
This $162,672 federal Project Grant award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research on the role of dopamine projections to the amygdala in goal-directed and habit learning. The principal investigator at the University of California, Los Angeles (UCLA) will conduct in-depth investigations using optogenetic manipulation and fiber photometry techniques to characterize the function of...
This $201,250 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to characterize the synaptic organization and connectivity of cholinergic interneurons in the nucleus accumbens (NAc) core region of the mouse brain. The research, conducted by New York University (NYU), aims to use a combination of anatomical, electrophysiological, and optogenetic techniques to map the diverse...
This $1,351,034 Project Grant award was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Alabama at Birmingham (UAB). The grant, which runs from April 2025 to February 2030, will support research on the role of somatostatin-expressing interneurons in the prelimbic region of the medial prefrontal cortex in regulating natural and drug reward seeking behaviors. The research aims to reveal the in vivo...
This federal Project Grant award of $165,792 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to expand the capabilities of behavioral segmentation approaches to provide a more comprehensive quantification of complex, spontaneous mouse behaviors. The award aims to implement an analysis pipeline to capture and analyze patterns of mouse body position, vocalizations, and arousal states, as well as explore the role of...
This federal Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the impact of fentanyl consumption on noradrenergic plasticity in the basolateral amygdala. The $184,706 award to the University of North Carolina at Chapel Hill will support a 5-year research project that seeks to: 1) characterize the patterns of fentanyl consumption and withdrawal and their effects on brainstem A2...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $206,955.00 in funding to the University of North Carolina at Chapel Hill. The award period runs from June 15, 2025 to May 31, 2027.

The overarching goal of this research project is to understand how different types of learned negative affect, such as from conditioned taste aversion, impact large-scale brain network activity. Specifically, the research will use rodent functional MRI and fiber photometry to investigate the effects of lithium chloride-induced conditioned taste aversion and cocaine-induced conditioned taste aversion on resting-state brain network activity and key neural node responses. This research aims to provide critical insights into how distinct forms of negative affect alter brain networks and their underlying neural processes, which could inform the understanding and treatment of substance use disorders and related psychiatric illnesses.

Generated 6/24/25, 5:58 AM